HIV-associated Burkitt lymphoma in the combination antiretroviral therapy era: real-world outcomes and prognostication

Chaoyu Wang,Jun Liu,Jieping Li,Yingyu Nan,Yao Liu

DOI: https://doi.org/10.21203/rs.3.rs-1806983/v1

2022-01-01

Abstract:Abstract We performed a retrospectively study to analyze the clinical characteristics and outcomes of HIV-associated Burkitt’s lymphoma in Chongqing University Cancer Hospital (CUCH), southwest China, from March 2012 to February 2022. In the entire cohort, the median age was 36 years (range, 28–60 years), and more patients were male (82.4%). The median CD4+ T cell count was 214/μl (range, 54-601), of whom 47.1% had a CD4+ T cell count below 200/μl. Most patients had elevated LDH, elevated β2-MG, extranodal involvement and advanced Ann Arbor stage at diagnosis. With a median follow-up of 11.5 months (range, 1.6-94.9 months), the overall 1-year PFS and OS rates were 27.6% and 47.6% respectively. The 1-year OS times in the LDH<3 upper limit of normal and LDH≥3 upper limit of normal groups were 62.5% and 31.3%, respectively (p=0.008). The 1-year OS times in the received <4 cycles and ≥4 cycles groups were 0 and 77.8%, respectively (p<0.001). These results demonstrated that LDH<3 upper limit of normal and received ≥4 cycles chemotherapy were significantly associated with improved outcomes. However, rituximab administration was not significantly associated with improved outcomes.